Session » B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster
- 10:30AM-12:30PM
-
Abstract Number: 0019
A Novel Product Candidate (CPTX2309) for In Vivo mRNA Engineering of Anti-CD19 CAR T Cells Utilizing Novel CD8-Targeted Lipid Nanoparticles
- 10:30AM-12:30PM
-
Abstract Number: 0005
Autoantibodies Identified in Myositis-Specific Autoantibody Negative Juvenile Myositis Patients
- 10:30AM-12:30PM
-
Abstract Number: 0004
Beyond Antibodies and CAR-T: Topologically Engineered, Superdimeric Antibody NK Engagers and T Cell Engagers for B Cell Depletion Demonstrating Cooperative Binding to Target and Effector Cells
- 10:30AM-12:30PM
-
Abstract Number: 0007
Bromodomain 2 of BET Proteins Plays a Crucial Role in Follicular/peripheral Helper T Cell and Plasma Cell Differentiation
- 10:30AM-12:30PM
-
Abstract Number: 0003
CLN-978, a CD19-directed T Cell Engager (TCE), Leads to Rapid and Deep B Cell Depletion and Has Broad Potential for Development in Autoimmune Diseases
- 10:30AM-12:30PM
-
Abstract Number: 0009
Comprehensive Autoantibody Profiling Highlights Clinical Relevance of Autoantibodies to G Protein-coupled Receptors in Systemic Sclerosis: Insights from a B-cell Depletion Clinical Trial
- 10:30AM-12:30PM
-
Abstract Number: 0012
Dichotomous Expression of CXCR3 and CCR9 and Relationship to Intestinal Permeability in B Cells in Rheumatoid Arthritis
- 10:30AM-12:30PM
-
Abstract Number: 0016
Establishment of a Human 3D In-Vitro Lymphoid Model to Evaluate Germinal Center Biology
- 10:30AM-12:30PM
-
Abstract Number: 0006
NX-5948, a Clinical-Stage BTK Degrader, Achieves Deep Suppression of BCR, TLR, and FcR Signaling in Immune Cells and Demonstrates Efficacy in Preclinical Models of Arthritis and Other Inflammatory Diseases
- 10:30AM-12:30PM
-
Abstract Number: 0014
Phenotypic Validation of Humanized IgA1 and CD89 Transgenic Mice as a Model for IgA Nephropathy-Like Autoimmune Disease
- 10:30AM-12:30PM
-
Abstract Number: 0010
Precision Editing of Cyclophilin a to Engineer Cyclosporine- and Voclosporin- Resistant Human CAR-T Cells
- 10:30AM-12:30PM
-
Abstract Number: 0018
Preclinical Analysisof CB-010, an Allogeneic anti-CD19CAR-T Cell Therapywith a PD-1 Knockout, for the Treatment of Patients with Refractory Systemic Lupus Erythematosus (SLE)
- 10:30AM-12:30PM
-
Abstract Number: 0008
Preclinical Development and Manufacturability of KYV-201, an Investigational Allogeneic Anti-CD19 Chimeric Antigen Receptor T Cell for the Treatment of Autoimmune Disease
- 10:30AM-12:30PM
-
Abstract Number: 0002
Preclinical Evaluation of BCMA And/or CD19 Nanobody-based Single or Compound CAR-T Cells Targeting B and Plasma Cells Associated with Autoimmune Disorders
- 10:30AM-12:30PM
-
Abstract Number: 0011
Preclinical Manufacturability and Activity of KYV-102 from Patients with Systemic Lupus Erythematosus Using Ingenui-T: A Rapid, Autologous Chimeric Antigen Receptor T-Cell Manufacturing Solution Utilizing Whole Blood
- 10:30AM-12:30PM
-
Abstract Number: 0013
Preclinical Polypharmacology of S-1117, a Novel Engineered Fc-fused IgG Degrading Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases
- 10:30AM-12:30PM
-
Abstract Number: 0015
Profiling of B and T Cells in Kidney Biopsies from ANCA-associated Vasculitis Patients with Glomerulonephritis at Single-Cell Resolution
- 10:30AM-12:30PM
-
Abstract Number: 0017
Syndecan-1 Plays a Role in the Pathogenesis of Sjögren’s Syndrome by Inducing B-cell Chemotaxis Through CXCL13-heparan Sulfate Interaction
- 10:30AM-12:30PM
-
Abstract Number: 0001
Type I Interferon and Anifrolumab Effects on Bone Marrow and Blood Plasma Cells in Systemic Lupus Erythematosus